Periodic Reporting for period 3 - HOPE (Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6)

Cancer immunotherapy that targets surface receptors like CTLA4 and/or PD1 with recombinant antibodies (a treatment regimen named immune checkpoint blockade; ICB) or personalized chimeric antigen receptor-engineered T cell immunotherapy (CAR-T) have emerged as innovative...